DK2421527T3 - Fremgangsmåder til forbedring af farmakokinetik - Google Patents
Fremgangsmåder til forbedring af farmakokinetik Download PDFInfo
- Publication number
- DK2421527T3 DK2421527T3 DK10714883.5T DK10714883T DK2421527T3 DK 2421527 T3 DK2421527 T3 DK 2421527T3 DK 10714883 T DK10714883 T DK 10714883T DK 2421527 T3 DK2421527 T3 DK 2421527T3
- Authority
- DK
- Denmark
- Prior art keywords
- ritonavir
- hcv
- pharmaceutically acceptable
- inhibitor
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (5)
- 1. Forbindelse med formlen I, fri base eller et farmaceutisk acceptabelt salt deraf,og ritonavir, eller et farmaceutisk acceptabelt salt deraf, til anvendelse ved behandling af en hepatitis C virusinfektion i en patient med behov for dette.
- 2. Forbindelse med formlen I, fri base eller farmaceutisk acceptabelt salt deraf, og ritonavir, eller et farmaceutisk acceptabelt salt deraf, til anvendelse ved behandling af en hepatitis C virusinfektion i en patient med behov for dette ifplge krav 1, der omfatter ko-administration med en forbindelse med formlen I, og ritonavir, mindst et yderligere middel valgt blandt et immunomodulerende middel og/eller et antiviralt middel og/eller en anden HCB NS 3/4A-proteasehsemmer og/eller NS5B-polymcrascha:mmcr og/eller en bredspektret viral hsemmer og/eller en anden cytochrom P-450-h£emmer.
- 3. Farmaceutisk sammenssetning omfattende en forbindelse med formlen I, eller fri base eller andet farmaceutisk acceptabelt salt deraf, og en cytochrom P450-monooxygcnaschcemmcr eller et farmaceutisk acceptabelt salt deraf, og mindst et farmaceutisk acceptabelt hjselpestof, diluent eller bserer, hvor cytochrom P450-monooxygenaseh£emmeren er ritonavir eller et farmaceutisk acceptabelt salt deraf.
- 4. Et kit omfattende en hepatitis C virus NS3-protcascha:mmcr ifplge formel I og ritonavir.
- 5. Farmaceutisk pakning omfattende en forbindelse ifplge formel I, ritonavir, og en indlsegsseddel, der indeholder anvisninger for anvendelse af hsemmerne.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17272209P | 2009-04-25 | 2009-04-25 | |
| PCT/EP2010/055317 WO2010122087A1 (en) | 2009-04-25 | 2010-04-22 | Methods for improving pharmacokinetics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2421527T3 true DK2421527T3 (da) | 2018-08-13 |
Family
ID=42236685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10714883.5T DK2421527T3 (da) | 2009-04-25 | 2010-04-22 | Fremgangsmåder til forbedring af farmakokinetik |
Country Status (36)
| Country | Link |
|---|---|
| US (4) | US20100272682A1 (da) |
| EP (1) | EP2421527B1 (da) |
| JP (1) | JP5523552B2 (da) |
| KR (1) | KR101471238B1 (da) |
| CN (2) | CN102413827A (da) |
| AR (1) | AR076388A1 (da) |
| AU (1) | AU2010240893B2 (da) |
| BR (1) | BRPI1015147B1 (da) |
| CA (1) | CA2758644C (da) |
| CL (1) | CL2011002643A1 (da) |
| CO (1) | CO6440593A2 (da) |
| CR (1) | CR20110551A (da) |
| DK (1) | DK2421527T3 (da) |
| EC (1) | ECSP11011420A (da) |
| ES (1) | ES2683736T3 (da) |
| HK (1) | HK1215858A1 (da) |
| HR (1) | HRP20181306T1 (da) |
| HU (1) | HUE040182T2 (da) |
| IL (1) | IL215620A (da) |
| LT (1) | LT2421527T (da) |
| MA (1) | MA33212B1 (da) |
| MX (2) | MX2011011105A (da) |
| MY (1) | MY169734A (da) |
| NZ (1) | NZ595917A (da) |
| PE (1) | PE20120638A1 (da) |
| PL (1) | PL2421527T3 (da) |
| PT (1) | PT2421527T (da) |
| RS (1) | RS57501B1 (da) |
| RU (1) | RU2591830C2 (da) |
| SG (1) | SG175328A1 (da) |
| SI (1) | SI2421527T1 (da) |
| TR (1) | TR201809600T4 (da) |
| TW (1) | TWI468160B (da) |
| UA (1) | UA103801C2 (da) |
| WO (1) | WO2010122087A1 (da) |
| ZA (1) | ZA201107421B (da) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AP2011005695A0 (en) * | 2008-10-15 | 2011-06-30 | Intermune Inc | Therapeutic antiviral poptides. |
| AR075584A1 (es) | 2009-02-27 | 2011-04-20 | Intermune Inc | COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO. |
| EP2455068A1 (en) * | 2010-11-09 | 2012-05-23 | F. Hoffmann-La Roche AG | Pharmaceutical composition for treating HCV infections |
| CA2811250C (en) | 2011-10-21 | 2015-08-11 | Abbvie Inc. | Methods for treating hcv |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| GB2506086A (en) | 2011-10-21 | 2014-03-19 | Abbvie Inc | Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| CA2863002A1 (en) | 2012-01-11 | 2013-07-18 | Abbvie Inc. | Processes for making hcv protease inhibitors |
| US20140024613A1 (en) * | 2012-06-27 | 2014-01-23 | Abbvie Inc. | Methods for Treating HCV |
| MX2015004411A (es) | 2012-10-08 | 2016-04-06 | Abbvie Inc | Compuestos utiles para elaborar inhibidores de proteasa de virus de la hepatitis c (vhc). |
| US10076512B2 (en) | 2014-05-01 | 2018-09-18 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
| HUE044606T2 (hu) * | 2014-05-01 | 2019-11-28 | Eiger Biopharmaceuticals Inc | A hepatitis delta vírusfertõzés kezelése |
| US11311519B2 (en) | 2014-05-01 | 2022-04-26 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
| DK3285768T3 (da) | 2015-04-21 | 2021-01-25 | Eiger Biopharmaceuticals Inc | Farmaceutiske sammensætninger omfattende lonafarnib og ritonavir |
| US11192914B2 (en) | 2016-04-28 | 2021-12-07 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
| CN117105928B (zh) * | 2023-08-22 | 2024-03-26 | 上海蓝木化工有限公司 | 一种蛋白酶抑制剂及其制备方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69332616T2 (de) | 1992-12-29 | 2003-11-06 | Abbott Laboratories, Abbott Park | Hemmer der retroviralen Protease |
| IL110752A (en) | 1993-09-13 | 2000-07-26 | Abbott Lab | Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor |
| US5559158A (en) | 1993-10-01 | 1996-09-24 | Abbott Laboratories | Pharmaceutical composition |
| IL111991A (en) | 1994-01-28 | 2000-07-26 | Abbott Lab | Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent |
| US6037157A (en) * | 1995-06-29 | 2000-03-14 | Abbott Laboratories | Method for improving pharmacokinetics |
| IL141438A0 (en) | 2000-02-23 | 2002-03-10 | Pfizer Prod Inc | Method of increasing the bioavailability and tissue penetration of azithromycin |
| CZ2003195A3 (cs) * | 2000-07-21 | 2003-04-16 | Schering Corporation | Peptidové inhibitory serinové proteázy NS3 a farmaceutický prostředek |
| RS20050461A (en) | 2002-12-16 | 2007-08-03 | Boehringer Ingelheim International Gmbh., | Use of a combination containing a non-nucleoside reverse transcriptase inhibitor (nnrt) with an inhibitor of cytochrome p450, such as protease inhibitors |
| PL1677827T3 (pl) * | 2003-10-27 | 2009-06-30 | Vertex Pharma | Połączenia do leczenia HCV |
| US20080161324A1 (en) * | 2006-09-14 | 2008-07-03 | Johansen Lisa M | Compositions and methods for treatment of viral diseases |
| US20120220520A1 (en) * | 2006-10-17 | 2012-08-30 | Van T Klooster Gerben Albert Eleutherius | Bioavailable combinations for hcv treatment |
-
2010
- 2010-04-22 LT LTEP10714883.5T patent/LT2421527T/lt unknown
- 2010-04-22 RS RS20180898A patent/RS57501B1/sr unknown
- 2010-04-22 MA MA34273A patent/MA33212B1/fr unknown
- 2010-04-22 NZ NZ595917A patent/NZ595917A/en unknown
- 2010-04-22 RU RU2011142651/15A patent/RU2591830C2/ru active
- 2010-04-22 WO PCT/EP2010/055317 patent/WO2010122087A1/en active Application Filing
- 2010-04-22 UA UAA201113756A patent/UA103801C2/ru unknown
- 2010-04-22 PT PT107148835T patent/PT2421527T/pt unknown
- 2010-04-22 KR KR1020117027997A patent/KR101471238B1/ko active IP Right Grant
- 2010-04-22 BR BRPI1015147-8A patent/BRPI1015147B1/pt active IP Right Grant
- 2010-04-22 MX MX2011011105A patent/MX2011011105A/es active IP Right Grant
- 2010-04-22 SG SG2011077732A patent/SG175328A1/en unknown
- 2010-04-22 ES ES10714883.5T patent/ES2683736T3/es active Active
- 2010-04-22 TR TR2018/09600T patent/TR201809600T4/tr unknown
- 2010-04-22 MX MX2013013597A patent/MX351185B/es unknown
- 2010-04-22 PE PE2011001850A patent/PE20120638A1/es active IP Right Grant
- 2010-04-22 EP EP10714883.5A patent/EP2421527B1/en active Active
- 2010-04-22 CA CA2758644A patent/CA2758644C/en active Active
- 2010-04-22 HU HUE10714883A patent/HUE040182T2/hu unknown
- 2010-04-22 CN CN2010800181204A patent/CN102413827A/zh active Pending
- 2010-04-22 TW TW99112703A patent/TWI468160B/zh active
- 2010-04-22 JP JP2012506491A patent/JP5523552B2/ja active Active
- 2010-04-22 MY MYPI2011005073A patent/MY169734A/en unknown
- 2010-04-22 PL PL10714883T patent/PL2421527T3/pl unknown
- 2010-04-22 AU AU2010240893A patent/AU2010240893B2/en active Active
- 2010-04-22 DK DK10714883.5T patent/DK2421527T3/da active
- 2010-04-22 SI SI201031725T patent/SI2421527T1/sl unknown
- 2010-04-22 CN CN201510706536.XA patent/CN105233249A/zh active Pending
- 2010-04-23 AR ARP100101352A patent/AR076388A1/es not_active Application Discontinuation
- 2010-04-23 US US12/766,051 patent/US20100272682A1/en not_active Abandoned
-
2011
- 2011-10-06 IL IL215620A patent/IL215620A/en active IP Right Grant
- 2011-10-10 ZA ZA2011/07421A patent/ZA201107421B/en unknown
- 2011-10-12 CO CO11135691A patent/CO6440593A2/es active IP Right Grant
- 2011-10-19 CR CR20110551A patent/CR20110551A/es unknown
- 2011-10-24 CL CL2011002643A patent/CL2011002643A1/es unknown
- 2011-10-25 EC EC2011011420A patent/ECSP11011420A/es unknown
-
2016
- 2016-04-05 HK HK16103828.4A patent/HK1215858A1/zh unknown
-
2017
- 2017-01-12 US US15/404,398 patent/US20170119739A1/en not_active Abandoned
-
2018
- 2018-07-11 US US16/033,177 patent/US20180318267A1/en not_active Abandoned
- 2018-08-10 HR HRP20181306TT patent/HRP20181306T1/hr unknown
-
2020
- 2020-04-08 US US16/842,855 patent/US10918626B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10918626B2 (en) | Method for improving pharmacokinetics | |
| RU2393863C2 (ru) | Лекарственные формы | |
| US20100189688A1 (en) | Dose forms comprising VX-950 and their dosage regimen | |
| KR20110116136A (ko) | Ｈｃｖ 및 ｈｉｖ 감염의 치료에 사용하기 위한 사이클로스포린 유도체 | |
| WO2008024843A2 (en) | Combination therapy method for treating hepatitis c virus infection and pharmaceutical compositions for use therein | |
| US20110117055A1 (en) | Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds | |
| EP2922596B1 (en) | Heterocyclyl carboxamides for treating viral diseases | |
| CN104812383A (zh) | 治疗hcv感染的治疗剂组合 | |
| AU2013203132A1 (en) | Methods for improving pharmacokinetics | |
| Abd Elguaad | Study on HCV direct acting drugs in treatment of chronic hepatitis C |